Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Skin Neoplasms × spartalizumab × Clear all

Phase

Status

Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 8 Carcinoma, Non-Small-Cell Lung 8 Carcinoma, Renal Cell 7 Pancreatic Neoplasms 4 Colorectal Neoplasms 4 Triple Negative Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Stomach Neoplasms 2 Neoplasms 2 Lymphoma 2 Head and Neck Neoplasms 2 Glioblastoma 2 Gastrointestinal Stromal Tumors 2 Esophageal Neoplasms 2 von Hippel-Lindau Disease 1 Urinary Bladder Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumors 1 Skin Neoplasms 1 Sarcoma, Alveolar Soft Part 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Paraganglioma 1 Mesothelioma, Malignant 1 Intermediate Risk Prostate Cancer 1 Hereditary leiomyomatosis and renal cell cancer 1

Interventions

Cyclophosphamide 11 fludarabine 8 aldesleukin 8 fludarabine phosphate 6 pembrolizumab 5 Nivolumab 4 Ipilimumab 4 Interleukin-2 4 dabrafenib 2 Vemurafenib 2 Biopsy 2 Aminolevulinic Acid 2 varlilumab 1 trametinib 1 tilsotolimod 1 spartalizumab 1 sotigalimab 1 sonidegib 1 smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1 glembatumumab vedotin 1 eprenetapopt 1 encorafenib 1 cemiplimab 1 cabozantinib 1 binimetinib 1 bempegaldesleukin 1 abobotulinumtoxinA 1 X-Rays 1 Tranexamic Acid 1 Tacrolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02967692 2025-09-18

COMBI-i

Novartis

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡